drugset
drugset / Trial / NCT06361316

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

NCT06361316 ↗

Recruiting 53 enrolled Kuirong Jiang CSPC Ouyi Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.

Timeline

Start
2024-04-08
Primary completion
2025-03-25
Completion
2028-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 50 mg/m2 Intravenous
Background Oxaliplatin Small molecule 60 mg/m2 Intravenous
Background S-1 Small molecule 40 mg Oral
Background S-1 Small molecule 60 mg Oral

Indications

malignant pancreatic neoplasm